In type 2 diabetes trials (the SUSTAIN program), Ozempic produced an average weight loss of around 4.5 kg to 6.5 kg (roughly 10 to 14 lbs) over 52 weeks, depending on the dose
semaglutide consistently demonstrated superior glycemic control and weight loss versus either other anti-hyperglycemic agents or other GLP-1 RAs, in a variety of T2D patient cohorts [reviewed in (11)]
Given its effectiveness and if youre interested, we added the Weight Loss Program as part of the Pravan membership at no additional cost
To evaluate the convergence of published results, we first conduct a multi-level kernel density meta-analysis of studies reporting a positive association of ghrelin ( N comb = 353, 18 contrasts) and a negative association of GLP-1 ( N comb = 258, 12 contrasts) and reward responses measured using task functional magnetic resonance imaging (fMRI)
Lee DH, Lee IK, Jin SH, Steffes M, Jacobs DR Jr